Mononuclear Cells

Mononuclear Cells

A phase 1b/2 study of combination vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia

Jeffrey E. Lancet, Gail J. Roboz, Larry D. Cripe, Glenn C. Michelson, Judith A. Fox, Richard D. Leavitt, Tianling Chen, Rachael Hawtin, Adam R. Craig, Farhad Ravandi, Michael B. Maris, Robert K. Stuart, and Judith E. Karp

Haematologica. 2014; 99:xxx doi:10.3324/haematol.2014.114769

Vosaroxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. This study assessed the safety and tolerability of vosaroxin plus cytarabine in patients with relapsed/refractory acute myeloid leukemia. Escalating vosaroxin doses (10-minute infusion; 10-90 mg/m2; days 1, 4) were given in combination with cytarabine on 1 of 2 schedules: schedule A (24-hour continuous intravenous infusion, 400 mg/m2/day, days 1-5) or schedule B (2-hour intravenous infusion,1 g/m2/day, days 1-5).

Potential Small Guide RNAs for tRNase ZL from Human Plasma, Peripheral Blood Mononuclear Cells, and Cultured Cell Lines

Sho Ninomiya , Mitsuoki Kawano, Takashi Abe , Tatsuya Ishikawa , Masayuki Takahashi , Masato Tamura , Yoshiaki Takahashi , Masayuki Nashimoto

PLoS ONE Published March 2, 2015

Several pieces of evidence suggest that small RNA degradation products together with tRNase ZL appear to form another layer of the whole gene regulatory network. The degraded RNA such as a 5′-half-tRNA and an rRNA fragment function as small guide RNA (sgRNA) to guide the enzyme to target RNA.

A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies

SY Kim , J-W Theunissen , J Balibalos , S Liao-Chan , MC Babcock , T Wong , B Cairns , D Gonzalez , EH van der Horst , M Perez , Z Levashova , L Chinn , JA D‘Alessio , M Flory , A Bermudez , DY Jackson , E Ha , J Monteon , MF Bruhns , G Chen, and T-S Migone

Citation: Blood Cancer Journal (2015) 5, e316; doi:10.1038/bcj.2015.39 Published online 29 May 2015

Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin’s lymphoma.

Agonist antibody that induces human malignant cells to kill one another

Kyungmoo Yeaa , Hongkai Zhangb , Jia Xieb , Teresa M. Jonesb , Chih-Wei Linb , Walter Francesconic , Fulvia Bertond , Mohammad Fallahie , Karsten Sauerb,f, and Richard A. Lernerb

Proceedings of the National Academy of Sciences of the United States of America, Contributed by Richard A. Lerner, September 25, 2015

An attractive, but as yet generally unrealized, approach to cancer therapy concerns discovering agents that change the state of differentiation of the cancer cells. Recently, we discovered a phenomenon that we call “receptor pleiotropism” in which agonist antibodies against known receptors induce cell fates that are very different from those induced by the natural agonist to the same receptor

Identification of TL-Om1, an Adult T-Cell Leukemia (ATL) Cell Line, as Reference Material for Quantitative PCR for Human T-Lymphotropic Virus 1

Madoka Kuramitsu, Kazu Okuma, Makoto Yamagishi, Tadanori Yamochi, Sanaz Firouzi, Haruka Momose, Takuo Mizukami, Kazuya Takizawa, Kumiko Araki, Kazuo Sugamura, Kazunari Yamaguchi, Toshiki Watanabe, Isao Hamaguchi

Journal of Clinical Microbiology vol.53 no.2 , February 2015

Quantitative PCR (qPCR) for human T-lymphotropic virus 1 (HTLV-1) is useful for measuring the amount of integrated HTLV-1 proviral DNA in peripheral blood mononuclear cells. Many laboratories in Japan have developed different HTLV-1 qPCR methods. However, when six independent laboratories analyzed the proviral load of the same samples, there was a 5-fold difference in their results.

Human Umbilical Cord Blood Cells Induce Neuroprotective Change in Gene Expression Profile in Neurons After Ischemia Through Activation of Akt Pathway

Shahaduzzaman, M. D.; Mehta, Vijay; Golden, Jason E.; Rowe, Derrick D.; Green, Suzanne; Tadinada, Ramya; Foran, Elspeth A.; Sanberg, Paul R.; Pennypacker, Keith R.; Willing, Alison E.

Cell Transplantation, Volume 24, Number 4, 2015, pp. 721-735(15)

Human umbilical cord blood (HUCB) cell therapies have shown promising results in reducing brain infarct volume and most importantly in improving neurobehavioral function in rat permanent middle cerebral artery occlusion, a model of stroke. In this study, we examined the gene expression profile in neurons subjected to oxygen-glucose deprivation (OGD) with or without HUCB treatment and identified signaling pathways (Akt/MAPK) important in eliciting HUCB-mediated neuroprotective responses.

Subscribe to Our Blog

Stay current with the AllCells Blog. Get email updates with helpful resources for biomedical researchers:

Have a question? Let’s chat.